11.56
+0.43(+3.86%)
Currency In NaN
Address
4370 La Jolla Village Drive
San Diego, CA 92122
United States of America
Phone
858 225 7696
Sector
Healthcare
Industry
Biotechnology
Employees
22
First IPO Date
N/A
| Name | Title | Pay | Year Born |
| Dr. Tien-Li Lee M.D. | Chief Executive Officer, Secretary & Director | 703,099 | 1975 |
| Dr. Bryan Jones Ph.D. | Chief Operating Officer | 467,437 | 1964 |
| Dr. Manasi Sinha Jaiman M.D., M.P.H. | Chief Medical Officer | 503,943 | 1981 |
| Mr. Tom Bicsak Ph.D. | Head of Regulatory Affairs & Quality | 0 | N/A |
| Dr. Andreas Niethammer M.D., Ph.D. | Head of Translational Medicine | 0 | N/A |
| Mr. Nelson B. Sun M.B.A. | Chief Financial Officer | 0 | 1977 |
| Dr. Dvorit Samid Ph.D. | Executive Vice President of Medical Affairs | 0 | N/A |
| Dr. Zhenhuan Zheng Ph.D. | Chief Research Officer | 0 | N/A |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
